Trevena (NASDAQ:TRVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligand G protein-coupled receptor (GPCR) selective medicines. By leveraging its proprietary bias-ligand technology platform, Trevena aims to create therapies that preferentially activate beneficial signaling pathways while minimizing engagement of pathways linked to adverse effects. The company’s research efforts target areas of high unmet medical need, including pain management, cardiometabolic disorders and central nervous system conditions.
The company’s lead compound, oliceridine (also known by its brand name OLINVEO), is a G protein-biased μ-opioid receptor agonist designed for the treatment of moderate to severe acute pain in the hospital setting. OLINVEO received U.S. Food and Drug Administration approval for intravenous use and represents the first commercialized product born from Trevena’s bias-ligand approach. Clinical studies have demonstrated its potential to provide effective analgesia with a differentiated safety and tolerability profile compared to conventional opioids.
In addition to oliceridine, Trevena’s pipeline includes TRV027, an angiotensin II type 1 receptor biased ligand being evaluated for acute heart failure, and TRV250, a delta-opioid receptor selective agonist in development for the acute treatment of migraine. These programs exemplify Trevena’s strategy of applying its platform to multiple GPCR targets, with the aim of unlocking new therapeutic options across diverse disease areas.
Founded in 2007 and headquartered in Conshohocken, Pennsylvania, Trevena operates a research and development infrastructure in the United States. The company continues to advance its portfolio through clinical trials and strategic collaborations, with the goal of delivering safer, more effective therapies to patients around the world.
